About xbiotech inc - XBIT
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
XBIT At a Glance
XBiotech, Inc.
5217 Winnebago Lane
Austin, Texas 78744
| Phone | 1-512-386-2900 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -45,540,000.00 | |
| Sector | Health Technology | Employees | 85 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
XBIT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.519 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.976 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
XBIT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -535,764.706 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
XBIT Liquidity
| Current Ratio | 16.011 |
| Quick Ratio | 16.011 |
| Cash Ratio | 15.834 |
XBIT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -26.071 |
| Return on Equity | -28.232 |
| Return on Total Capital | -32.447 |
| Return on Invested Capital | -28.232 |
XBIT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |